opc 12759 has been researched along with Cancer of Head in 4 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies." | 2.90 | The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. ( Fujii, M; Konishi, T; Nagamoto, H; Shibasaki, Y; Ueno, T; Yurikusa, T; Zenda, S, 2019) |
| " The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3." | 2.84 | Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. ( Beppu, T; Fujii, M; Fujii, T; Fujimoto, Y; Hasegawa, Y; Hirano, S; Iwae, S; Kojima, H; Matsushima, Y; Matsuura, K; Monden, N; Naka, Y; Nishimori, H; Ogawa, T; Okami, K; Ota, I; Sasaki, K; Tahara, M; Takahashi, S; Tanaka, K; Ueda, S; Ueda, T; Yokota, T, 2017) |
| "60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization." | 2.84 | Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. ( Chaitanya, B; Chhaparwal, Y; Fernandes, D; Pai, KM; Yathiraj, PH, 2017) |
| "Chemoradiotherapy for head and neck cancer is associated with a high incidence of severe oral mucositis; an adverse, painful event." | 1.37 | [Investigation of how to prevent mucositis induced by chemoradiotherapy]. ( Hushimi, C; Inoue, T; Kamata, S; Kobayashi, M; Masubuchi, T; Miura, K; Moya, M; Tada, Y; Tajima, H; Tosaka, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Ogawa, T | 1 |
| Takahashi, S | 1 |
| Okami, K | 1 |
| Fujii, T | 1 |
| Tanaka, K | 1 |
| Iwae, S | 1 |
| Ota, I | 1 |
| Ueda, T | 1 |
| Monden, N | 1 |
| Matsuura, K | 1 |
| Kojima, H | 1 |
| Ueda, S | 1 |
| Sasaki, K | 1 |
| Fujimoto, Y | 1 |
| Hasegawa, Y | 1 |
| Beppu, T | 1 |
| Nishimori, H | 1 |
| Hirano, S | 1 |
| Naka, Y | 1 |
| Matsushima, Y | 1 |
| Fujii, M | 2 |
| Tahara, M | 1 |
| Chaitanya, B | 1 |
| Pai, KM | 1 |
| Yathiraj, PH | 1 |
| Fernandes, D | 1 |
| Chhaparwal, Y | 1 |
| Ueno, T | 1 |
| Zenda, S | 1 |
| Konishi, T | 1 |
| Yurikusa, T | 1 |
| Shibasaki, Y | 1 |
| Nagamoto, H | 1 |
| Tosaka, C | 1 |
| Tajima, H | 1 |
| Inoue, T | 1 |
| Moya, M | 1 |
| Kobayashi, M | 1 |
| Miura, K | 1 |
| Tada, Y | 1 |
| Masubuchi, T | 1 |
| Hushimi, C | 1 |
| Kamata, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer[NCT02085460] | Phase 2 | 94 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Investigators who had undergone specific training assessed the severity of oral mucositis twice every week. To evaluate the severity of oral mucositis objectively, the clinical findings of the oral mucosa as well as functional disorders and symptomatic aspects were recorded in the Oral Mucositis Assessment Sheet by each investigator. Photographic documentation of the oral mucosa was also submitted by each investigator, 3 days before or 57 days after initiation of chemoradiotherapy, or at the time of withdrawal. The Oral Mucositis Assessment Sheets and photographic documentation were then reviewed by the Oral Mucositis Evaluation Committee to grade the severity of oral mucositis according to the CTCAE 3.0.z (NCT02085460)
Timeframe: 77 days
| Intervention | percentage of participants (Number) |
|---|---|
| 2% Rebamipide Liquid | 29.0 |
| 4% Rebamipide Liquid | 25.0 |
| Placebo | 38.7 |
Day 1 was defined as the start of chemotherapy. (NCT02085460)
Timeframe: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 77
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | Day 50 | Day 57 | Day 64 | Day 71 | Day 77 | |
| 2% Rebamipide Liquid | 31 | 29 | 27 | 25 | 23 | 20 | 18 | 17 | 12 | 11 | 8 | 6 |
| 4% Rebamipide Liquid | 31 | 31 | 30 | 29 | 25 | 20 | 18 | 18 | 16 | 15 | 13 | 11 |
| Placebo | 31 | 30 | 29 | 23 | 23 | 19 | 16 | 15 | 13 | 11 | 8 | 8 |
3 trials available for opc 12759 and Cancer of Head
1 other study available for opc 12759 and Cancer of Head
| Article | Year |
|---|---|
[Investigation of how to prevent mucositis induced by chemoradiotherapy].
Topics: Alanine; Antineoplastic Agents; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; | 2011 |